Judy Torres
Judy Torres Shares Her Life Beyond the Spotlight in No Reason to Cry: A Memoir
Freestyle icon Judy Torres shares her journey from the Bronx to the stage and the personal challenges behind her public career in No Reason to Cry: A…
Archive
Press releases, October 2026
393 releases
FacePlus Plastic Surgery Institute
Lubbock Plastic Surgeon Dr. Thanapoom Boonipat Leads Suturing Workshop for Texas Tech Women in STEM Premed Students
Dr. Thanapoom "Mo" Boonipat, plastic surgeon and founder of FacePlus Plastic Surgery Institute in Lubbock, led a hands-on suturing workshop and…
ATIS
Why Elevator Consulting Is Shifting to Continuous, Data-Driven Oversight
Elevator and escalator consulting firms are moving from periodic reports to continuous data on equipment condition. ATIS has acquired AuditMate to…
McNeil Safety Consulting
Former Firefighter Michael Karl McNeil Says Hot Work Fire Prevention Starts Before the Torch Is Lit and Ends Well After It Goes Out
Former Fire Battalion Chief Michael Karl McNeil, a firefighter for 25 years, urges employers to treat welding, cutting and grinding as fire…
Calahan Bath, Kitchen and Sunrooms
Southeastern PA Homeowners Turn to Free Estimates to Plan Luxury Kitchen Remodels
A free estimate for a luxury kitchen remodel in West Chester gives southeastern Pennsylvania homeowners a firm scope, pricing and a visual plan…
Akeso, Inc.
Positive Overall Survival Results from the Phase III HARMONi-GI1 Trial of Ivonescimab Plus Chemotherapy Versus Durvalumab Plus Chemotherapy in First-Line Biliary Tract Cancer Presented at the ESMO 2026 Presidential Symposium
Akeso, Inc. (HKEX: 9926.HK) today announced the presentation of results from the randomized, controlled, double-blind, multicenter, registrational…
Johnson & Johnson
RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) combination demonstrates 77% overall response rate in first-line treatment of patients with advanced head and neck cancer
Responses were deep and durable, with 65% ongoing at clinical cutoff Results support continued evaluation of the investigational RYBREVANT FASPRO…
Blumenthal Nordrehaug Bhowmik De Blouw LLP
Employment & Labor Lawyers, at Blumenthal Nordrehaug Bhowmik De Blouw LLP, File Lawsuit Against Sinclair Television of California, LLC, for Alleged Failure to Provide Meal Periods and Rest Breaks
Allegedly, Sinclair Television of California, LLC failed to provide employees with accurate itemized wage statements due to missed meal breaks. This,…
Kelun-Biotech
The Results of Phase III OptiTROP-Lung06 Study of Sacituzumab Tirumotecan (sac-TMT) Presented as an ESMO Oral Presentation and Simultaneously Published in The New England Journal of Medicine
PFS was significantly prolonged: as assessed by BICR, the risk of disease progression or death was reduced by 51% (HR 0.49; 95% CI 0.36-0.65;…
Kelun-Biotech
Final OS Analysis Results from Phase III OptiTROP-Lung04 Study of Sacituzumab Tirumotecan (sac-TMT) Presented at 2026 ESMO
Median OS was extended by 8.5 months compared with platinum-based doublet chemotherapy (25.9 vs 17.4 months), with a 31% reduction in the risk of…
ExpertConsumers.org
Best AI Tools for Small Business Marketing (2026): CapCut Featured for Creating Professional Video and Visual Content by Expert Consumers
Expert Consumers has recognized CapCut in its 2026 coverage of the best AI tools for small business marketing, highlighting the platform's collection…
Consumer365.org
Best Protective iPhone Cases for 2026: Top Slim and Drop-Protection Options for iPhone 18 Pro & iPhone 18 Pro Max Recommended by Consumer365
Consumer365 has recognized TORRAS in its review of the best iPhone cases for 2026, highlighting the Ostand Q3 Air and Ostand Q3 Air Pro as two…
Eli Lilly and Company
New data on Lilly's investigational treatment olomorasib at ESMO 2026 show durable first-line activity in KRAS G12C-mutant non-small cell lung cancer
Data presented at ESMO highlight the promising efficacy of olomorasib in combination with standard-of-care immunotherapy with or without chemotherapy…
Johnson & Johnson
Johnson & Johnson reports 75% tumor response rate in advanced prostate cancer with JNJ-6143, a first-in-class RIPTAC™ molecule
JNJ-6143 is an investigational, once-daily, novel, small molecule designed to trigger cancer cell death through a targeted dual-protein lock between…
Innovent Biologics, Inc.
2026 ESMO | Innovent Announcement Phase 2 Data Presentation for IBI354 (HER2 ADC) In First-line Treatment of Breast Cancer
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and…
Ping An Insurance (Group) Company of China, Ltd.
Ping An Highlights Green Development Initiatives at International Communication Seminar in Shenzhen Ahead of APEC 2026
The Seminar on International Communication of Chinese and Foreign Enterprises' Green Development and Global Contributions was held at the Ping An…
Innovent Biologics
2026 ESMO | Innovent Presented Phase 1 Study Data for IBI3001, a First-in-Class EGFR/B7H3 Bispecific ADC
Innovent Biologics, Inc. (HKEX Stock Code: 01801), a biopharmaceutical company dedicated to the research, development, manufacturing, and…
Expo Contratista
Expo Contratista Announces 10th Edition in Dallas, Spotlighting Latino Construction Businesses and Workforce Development
October 1-2, 2027, event at Kay Bailey Hutchison Convention Center Dallas will feature Latino Build Show workshops and technical demonstrations.
IRAEmpire LLC
New Guide Titled "Gold Proof Coins vs Uncirculated Coins: Are Gold Proof Coins a Good Investment" Released
IRAEmpire has published a new guide on how to compare Gold proof coins with Gold uncirculated coins to help American consumers.
Zhejiang Wenda Pharmaceutical Technology Co., Ltd.
Zhejiang Wenda Pharma Announces Positive Results from Phase II Trial of Oral BET Inhibitor NHWD-870 HCl at the 2026 ESMO Annual Meeting
At the 2026 ESMO Annual Meeting, Zhejiang Wenda Pharmaceutical Technology Co., Ltd. ("Wenda Pharma") will publish the phase II clinical trial data…